Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
(USO 11025/ Novartis CBKM120ZUS39T) Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Breast Cancer Patients with Brain Metastases View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
(USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
(USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
(USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 1/2 Open-Label Study to Evaluate the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 1/2 Open-Label Study to Evaluate the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 1/2 Open-Label Study to Evaluate the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 1/2 Open-Label Study to Evaluate the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic
HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic
HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic
HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206) View
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib
vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic
HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206) View
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
(UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
(UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
(UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
(UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase II single-arm trial to investigate tepotinib in
advanced (Stage IIIB/IV) non-small cell lung cancer
with MET exon 14 (METex14) skipping alterations
(VISION) View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase II single-arm trial to investigate tepotinib in
advanced (Stage IIIB/IV) non-small cell lung cancer
with MET exon 14 (METex14) skipping alterations
(VISION) View
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase II single-arm trial to investigate tepotinib in
advanced (Stage IIIB/IV) non-small cell lung cancer
with MET exon 14 (METex14) skipping alterations
(VISION) View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View
Indication:
Mesothelioma
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Mesothelioma
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Mesothelioma
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Mesothelioma
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide.
View
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide.
View
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide.
View
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012) View
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Penile Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thymomas
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thymomas
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thymomas
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thymomas
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Downtown
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View
Indication:
Vaginal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase:
II
Title:
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View